Author of the publication

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

, , , , , , , , , , , and . Annals of hematology, 87 (9): 717–726 (2008)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma, , , , , , , , , and 1 other author(s). Clinical cancer research : an official journal of the American Association for Cancer Research, 18 (13): 3637–3647 (2012)Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL), , , , , , , , , and 5 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 19 (3): 545–552 (2008)Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF, , , , , , , , , and 3 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 12 (4): 471–477 (2001)CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group, , , , , , , , , and . Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 23 (5): 1267–1273 (2012)Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group, , , , , , , , , and . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 (3): 580–586 (1994)Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL, , , , , , , , , and 3 other author(s). Blood, 104 (3): 634–641 (2004)Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia, , , , , , , , , and 3 other author(s). Blood, 117 (10): 2918–2923 (2011)Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma, , , , , , , , , and . Blood, 107 (8): 3058–3064 (2006)MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas, , , , , , , , , and 5 other author(s). British journal of haematology, 142 (5): 732–744 (2008)Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60), , , , , , , , , and 16 other author(s). The Lancet Oncology, 9 (2): 105–116 (2008)